27September

Hyris to participate to SIBioC 2022 in Genova, presenting Hyris marketplace approach for laboratory medicine

Hyris to participate to SIBioC 2022 in Genova, presenting Hyris marketplace approach for laboratory medicine

From October 5th to October 7th, Hyris will be present at the SIBioC 2022 in Genova, to present Hyris marketplace approach and Hyris SystemTM disruptive featuresfor laboratory medicine.

Our team will discuss with partners and prospects at Hyris stand First Floor, bar area.

 

Posted in Events

20September

Hyris to participate in SEI 2022 in Leon, hosted by the Sociedad Española de Immunologia

Hyris to participate in SEI 2022 in Leon, hosted by the Sociedad Española de Immunologia

From September 22nd to September 24th, Hyris will be present at the SEI 2022 in Leon, to show the scientific approach related to our new T Cells test to monitor the cellular immunity to SARS-CoV-2.

On September 22nd at 1pm our Product Specialist Matteo Audano will hold a talk at the dedicated symposium titled "Development of a PCR diagnostic test to monitor the viral cellular immunity".

 

Posted in Events

08August

Hyris' new T-cell Test is finally available to EU Countries to easily map patients' cellular immunity to SARS-CoV-2.

Hyris' new T-cell Test is finally available to EU Countries to easily map patients' cellular immunity to SARS-CoV-2.

After months of experimentation in partnership with some world-class schools of medicine and top-tier diagnostic providers, our much-anticipated T-Cell Test based on innovative qPCR technology is finally available for the European market with a CE-IVD mark. The new Test will change the way laboratories and diagnostic providers track and monitor T-cell patients' immunity to SARS-CoV-2, leveraging the unique characteristics of Hyris System™.

Posted in bKIT, Products

27June

Hyris presented Hyris System, its distruptive signature technology, at Analytica 2022 in Munich

Hyris presented Hyris System, its distruptive signature technology, at Analytica 2022 in Munich

Hyris presented its Hyris System™ and the new T Cells test in Munich last week, at Analytica 2022, the world largest laboratory technology fair.

Posted in Events

13June

A new T-cell activation assay based on Hyris technology marks a disruptive approach for the detection of SARS-CoV-2 specific cellular immunity.

A new T-cell activation assay based on Hyris technology marks a disruptive approach for the detection of SARS-CoV-2 specific cellular immunity.

A scientific paper recently published in Nature Biotechnology reveals new research regarding how we track and monitor T-cell patients’ immunity to SARS-CoV-2, leveraging the unique characteristics of Hyris System™. The study results from a joint effort of an international research team from the Icahn School of Medicine at Mount Sinai, Singapore Duke-NUS Medical School, laboratory diagnostic service providers Synlab, and Hyris.

Posted in Products

22March

Hyris and its network want to make pragmatic impact Helping Ukrainian Families

Hyris and its network want to make pragmatic impact Helping Ukrainian Families

Hyris is actively following the humanitarian crisis caused by Russian invasion of Ukraine started on February 24th. We have colleagues, friends and business partners in Ukraine. Since the beginning, we tried to actively help our colleagues and friends’ families to reach a safe place outside of Kiev. And, in case possible, outside of Ukraine.

Posted in Events

21December

Hyris presented its new, disruptive T-Cell test at the international conference "A-Wish", fully embracing the Immunology sector to better fight COVID-19 and beyond.

Hyris presented its new, disruptive T-Cell test at the international conference

On December 17th 2021 Hyris presented its new test to detect the body's T Cell immune response to SARS-CoV-2 on 17 December 2021, at "A-WISH", Alicante-Winter Immunology Symposium in Health, which addressed strategies for the COVID-19 response and the development of the vaccines against SARS-CoV-2.

Posted in Products

02December

Hyris releases its new Demo to better support all prospect users of its portable and reliable molecular test for diagnosing SARS-CoV-2 into human subjects.

Hyris releases its new Demo to better support all prospect users of its portable and reliable molecular test for diagnosing SARS-CoV-2 into human subjects.

With the SARS-CoV-2 pandemic still causing further disruption of public security and companies’ workflows worldwide, Hyris keeps supporting medical professionals and researchers testing the presence of SARS-CoV-2 into human beings. A fresh, new demo immed

Posted in Products

14October

Hyris new Test can quickly detect the body's T Cell immune response to SARS-CoV-2.

Hyris new Test can quickly detect the body's T Cell immune response to SARS-CoV-2.

Hyris developed a rapid T-Cell test, which leverages the power of the Hyris SystemTM to track patients' immunity levels to SARS-CoV-2 for research and global clinical use. The new test has been brought to market after having inked an exclusive licensing agreement with Singapore Duke-NUS Medical School.

Posted in Products, Events

15September

Hyris presents its new Brand, supporting its fast growth worldwide.

Hyris presents its new Brand, supporting its fast growth worldwide.

Hyris is proud to introduce its new brand identity and communication system, a further step to better sustain its commitment towards customers, partners, investors. The new Hyris Brand marks an important milestone in the Company evolution journey, which will continue at the forefront of biotech innovation and industry disruption.

Posted in Events

01June

The Hyris System™ can detect SARS-CoV-2 despite all the novel variants - Update

The Hyris System™ can detect SARS-CoV-2 despite all the novel variants - Update

As the new mutations of SARS-CoV-2 keep spreading world-wide, significant concerns increasingly worry both citizenship and the institutions. Even if some of these variants are innocuous, others may give the virus a selective advantage. Based on a risk assessment by major authorities involved in the fight against the spread of COVID-19, such as WHO, ECDC, CDC, these mutations are identified as Variants of Concern and monitored, alerting even more globally scientific and medical communities.

Posted in Technology, Research

15April

The Canadian Olympic Committee and Canadian Paralympic Committee chose the HYRIS SYSTEM™ to effectively test Canadian National Sport Teams against Covid-19.

The Canadian Olympic Committee and Canadian Paralympic Committee chose the HYRIS SYSTEM™ to effectively test Canadian National Sport Teams against Covid-19.

After the successful deployment for top Hockey Teams in the previous months, the HYRIS SYSTEM™ has been chosen by the Canadian Olympic Committee and Canadian Paralympic Committee to support in the face of the pandemic another national sport much appreciated by the Canadians: curling.

Posted in Technology

22February

The Hyris System™ can detect SARS-CoV-2 despite all the novel variants

The Hyris System™ can detect SARS-CoV-2 despite all the novel variants

As the new mutations of SARS-CoV-2 keep spreading world-wide, significant concerns increasingly worry both citizenship and the institutions. Even if some of these variants are innocuous, others may give the virus a selective advantage. Based on a risk assessment by major authorities involved in the fight against the spread of COVID-19, such as WHO, ECDC, CDC, these mutations are identified as Variants of Concern and monitored, alerting even more globally scientific and medical communities.

Posted in Technology, Research

11February

Lallemand Health Solutions choose the Hyris System™ for their internal certification protocol

Lallemand Health Solutions choose the Hyris System™ for their internal certification protocol

We are excited to announce that Lallemand Health Solutions, a leading world-class probiotic manufacturer, chose the Hyris System™ for their internal certification protocol to produce and supply the best probiotic strains and products.

Posted in Technology, Research

31December

Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection

Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection

Hyris CE-IVD marked test for COVID human diagnostic "bKIT Virus Finder COVID-19" is at the core of the signature Article "Evaluation of the diagnostic accuracy of a new point-of-care rapid test for SARS-CoV-2 virus detection", from the Department of Laboratory Medicine of the National Institute for The Study and Treatment of Cancer IRCCS "Fondazione G Pascale" (IRCCS Pascale), of Naples (Italy)

Posted in Technology

[12 3  >>  

Newsletter

Subscribe our newsletter for periodical updates about Hyris solutions.

Address


Headquarter

London

Lower Ground Floor
One George Yard
EC3V 9DF - London, UK
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Center

Milan

Viale Lancetti 19
20158 Milan, Italy

  • This email address is being protected from spambots. You need JavaScript enabled to view it.

C.so Garibaldi 60
Milano 20121, Italy
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

Hyris APAC - R&D Center of Excellence

Singapore

38 19 Cecil Street #04-01
The Quadrant at Cecil
Singapore (049704)
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

US West Coast Sales Inquiries

Los Gatos

  • This email address is being protected from spambots. You need JavaScript enabled to view it.

Social